Bio[M] | Lonza Pharma & Biotech

maximising success, taking new biotherapeutics from discovery to clinic...

Digitally delivered
Thursday 18 June 2020

A one-day Bio[M] and Lonza virtual symposium, to gain insight and discuss

Bio[M] and Lonza are pleased to invite you to join them for a complimentary symposium, **digitally delivered on Thursday 18 June 2020,** to gain insight from experts, in the different approaches and techniques to successfully progress therapeutic proteins from discovery to the clinic.

Enjoy an industry perspective from a seasoned pharmaceutical executive, together with updates to approaches with new and established technologies enabling translational research, from Lonza specialists, local companies and leading academics.

Pre-book 1-on-1 sessions with our scientific experts at the Virtual Drop-in-Clinics that will follow the presentations.

Registration

Attendance at this event is complimentary and by invitation.
For more information, including the latest agenda and to register, please visit:

www.bio-m.org//BioM_Lonza_Virtual_Symposium_18_June_2020

Virtual symposium digitally delivered

The Symposium is kindly hosted by:
Lonza and Bio[M]

Local companies and academics presenting will be from southern Germany and Switzerland with a focus on biologics programs.

Agenda on reverse side.

Bio[M] | Lonza Pharma & Biotech

Insight and discussion with our experts

Agenda (all times CET)

09.00 – 09.10	**Welcome:** Horst Domdey , CEO, Bio[M] Sarah Holland | Global Head of Licensing, Lonza
09.10 – 09.45	**Keynote: An Industry perspective – What to consider when moving therapeutic proteins from development to first in human trials** Hari Kumar | Pharmaceutical Executive; Independent Board Member; former CEO Adheron Therapeutics
09.45 – 10:20	**Developability assessment tools and de-risking strategies to support progression of biologics from discovery to development** Noel Smith | Principal, Applied Protein Services, Lonza
10:20 – 10.45	**Local company presentation – Title TBC** Speaker – TBC
10.50 – 11.00	Virtual coffee break
11.00 – 11.35	**Approaches to maximise successful development of cell lines expressing more complex proteins – including bispecific antibodies** Alison Porter | Head of Expression System Sciences, Lonza
11.35 – 12.00	**Local company presentation** Speaker – TBC
12.00 – 12.35	**A step forward – Combined strategies to enhance the performance of *Pichia pastoris*** Joachim Klein | Head of Strain Development and Cell Banking, Microbial Development Services, Lonza
12.35 – 13.00	**Local company presentation** Speaker – TBC
13.00 – 13.30	Virtual lunch break
13.30 – 13.55	**Local company presentation | Virtual Drop-in-Clinics start** Speaker – TBC
13.55 – 14.20	**Local company presentation | Virtual Drop-in-Clinics continue** Speaker – TBC
14.20 – 15.00	**Q&A session with all speakers | Virtual Drop-in-Clinics continue**
15.00	Virtual symposium ends

Hari Kumar – With over 25 years of experience in the pharmaceutical industry, Hari has held leadership roles at Roche, Eisai, Amira Pharma, and Panmira Pharma. In 2013 Hari joined Adheron Therapeutics Inc as CEO which he successfully led until acquired in 2015. Hari is currently focused on helping biotech start-ups with their strategies either as an independent board member, or as a consultant to the CEO.

All trademarks belong to Lonza or its affiliates or to their respective third party owners and are only being used for informational purposes.
©2020 Lonza. All rights reserved.